vorinostat has been researched along with Aggressive Systemic Mastocytosis in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Aggressive Systemic Mastocytosis: A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lyberg, K | 1 |
Ali, HA | 1 |
Grootens, J | 1 |
Kjellander, M | 1 |
Tirfing, M | 1 |
Arock, M | 1 |
Hägglund, H | 1 |
Nilsson, G | 1 |
Ungerstedt, J | 1 |
1 other study available for vorinostat and Aggressive Systemic Mastocytosis
Article | Year |
---|---|
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Topics: Acetylation; Case-Control Studies; Cell Line; Cell Proliferation; Cell Survival; DNA Methylation; Do | 2017 |